Literature DB >> 25987102

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

H Suen1, R Brown1, S Yang1, P J Ho1, J Gibson1, D Joshua1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25987102     DOI： 10.1038/leu.2015.104

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors:  A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

2.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

3.  Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts.

Authors:  J Monteiro; F Batliwalla; H Ostrer; P K Gregersen
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

4.  Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.

Authors:  D M Sze; G Giesajtis; R D Brown; M Raitakari; J Gibson; J Ho; A G Baxter; B Fazekas de St Groth; A Basten; D E Joshua
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

5.  Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.

Authors:  Ross D Brown; Andrew Spencer; Phoebe Joy Ho; Nola Kennedy; Karieshma Kabani; Shihong Yang; Daniel M Sze; Esther Aklilu; John Gibson; Douglas E Joshua
Journal:  Leuk Lymphoma       Date:  2009-11

6.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Authors:  C Bryant; H Suen; R Brown; S Yang; J Favaloro; E Aklilu; J Gibson; P J Ho; H Iland; P Fromm; N Woodland; N Nassif; D Hart; D E Joshua
Journal:  Blood Cancer J       Date:  2013-09-13       Impact factor: 11.037
  6 in total
  34 in total

Review 1.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

2.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

3.  T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Authors:  Fabienne Lucas; Michael Pennell; Ying Huang; Don M Benson; Yvonne A Efebera; Maria Chaudhry; Tiffany Hughes; Jennifer A Woyach; John C Byrd; Suohui Zhang; Desiree Jones; Xiangnan Guan; Christin E Burd; Ashley E Rosko
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-21       Impact factor: 5.742

4.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

5.  Biomimetic Nanoparticle Vaccines for Cancer Therapy.

Authors:  Ashley V Kroll; Yao Jiang; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Biosyst       Date:  2018-11-13

Review 6.  Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

Authors:  David A Braun; Catherine J Wu
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

Review 7.  Checkpoint inhibition in myeloma.

Authors:  Don M Benson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

9.  Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.

Authors:  Slavica Vuckovic; Christian E Bryant; Ka Hei Aleks Lau; Shihong Yang; James Favaloro; Helen M McGuire; Georgina Clark; Barbara Fazekas de St Groth; Felix Marsh-Wakefield; Najah Nassif; Edward Abadir; Vinay Vanguru; Derek McCulloch; Christina Brown; Stephen Larsen; Scott Dunkley; Liane Khoo; John Gibson; Richard Boyle; Douglas Joshua; P Joy Ho
Journal:  Blood Adv       Date:  2020-10-13

Review 10.  Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Authors:  Matthew J Pianko; Alison J Moskowitz; Alexander M Lesokhin
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.